REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

BACKGROUND: A phase 3, multinational, randomized, non-inferiority trial (REFLECT) compared the efficacy and safety of lenvatinib (LEN) and sorafenib (SOR) in patients with unresectable hepatocellular carcinoma (uHCC). LEN had an effect on overall survival (OS) compared to SOR, statistically confirme...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Gastroenterol
Main Authors: Yamashita, Tatsuya, Kudo, Masatoshi, Ikeda, Kenji, Izumi, Namiki, Tateishi, Ryosuke, Ikeda, Masafumi, Aikata, Hiroshi, Kawaguchi, Yasunori, Wada, Yoshiyuki, Numata, Kazushi, Inaba, Yoshitaka, Kuromatsu, Ryoko, Kobayashi, Masahiro, Okusaka, Takuji, Tamai, Toshiyuki, Kitamura, Chifumi, Saito, Kenichi, Haruna, Katsuya, Okita, Kiwamu, Kumada, Hiromitsu
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Japan 2019
Assuntos:
Original Article—Liver, Pancreas, and Biliary Tract
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6942573/
https://ncbi.nlm.nih.gov/pubmed/31720835
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00535-019-01642-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados